Lorenz; Douglas A.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Lorenz; Douglas A..The latest application filed is for "pharmaceutical compositions of dispersions of drug and neutral polymers".

Company Profile

0.17.22

Lorenz; Douglas A. - Bend OR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Pharmaceutical Compositions Of Dispersions Of Drug And Neutral Polymers App 20160374945 - Friesen; Dwayne T. ; et al.	2016-12-29
Pharmaceutical compositions of dispersions of drug and neutral polymers Grant 9,468,604 - Friesen , et al. October 18, 2	2016-10-18
Pharmaceutical compositions providing enhanced drug concentrations Grant 9,457,095 - Curatolo , et al. October 4, 2	2016-10-04
Pharmaceutical Compositions Providing Enhanced Drug Concentrations App 20150190518 - Curatolo; William J. ; et al.	2015-07-09
Pharmaceutical compositions providing enhanced drug concentrations Grant 8,980,321 - Curatolo , et al. March 17, 2	2015-03-17
Pharmaceutical Compositions Providing Enhanced Drug Concentrations App 20140322325 - Curatolo; William J. ; et al.	2014-10-30
Pharmaceutical compositions providing enhanced drug concentrations Grant 8,796,341 - Curatolo , et al. August 5, 2	2014-08-05
Pharmaceutical Compositions Of Dispersions Of Drug And Neutral Polymers App 20140210117 - Friesen; Dwayne T. ; et al.	2014-07-31
Pharmaceutical Compositions Providing Enhanced Drug Concentrations App 20130345236 - Curatolo; William J. ; et al.	2013-12-26
Pharmaceutical compositions providing enhanced drug concentrations Grant 8,501,231 - Curatolo , et al. August 6, 2	2013-08-06
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors Grant 8,389,011 - Crew , et al. March 5, 2	2013-03-05
Pharmaceutical Compositions Providing Enhanced Drug Concentrations App 20120259022 - Curatolo; William J. ; et al.	2012-10-11
Pharmaceutical compositions providing enhanced drug concentrations Grant 8,202,912 - Curatolo , et al. June 19, 2	2012-06-19
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors Grant 8,197,848 - Crew , et al. June 12, 2	2012-06-12
Pharmaceutical Compositions Providing Enhanced Drug Concentrations App 20110294902 - CURATOLO; William J. ; et al.	2011-12-01
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitor Grant 8,048,452 - Curatolo , et al. November 1, 2	2011-11-01
Pharmaceutical compositions providing enhanced drug concentrations Grant 8,026,286 - Curatolo , et al. September 27, 2	2011-09-27
Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor Grant 7,897,175 - Friesen , et al. March 1, 2	2011-03-01
Process for forming amorphous atorvastatin Grant 7,655,692 - Lorenz , et al. February 2, 2	2010-02-02
Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Metho- xy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea App 20070287719 - Boyden; Tracy L. ; et al.	2007-12-13
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors App 20070282009 - Crew; Marshall D. ; et al.	2007-12-06
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors Grant 7,235,259 - Crew , et al. June 26, 2	2007-06-26
4-Amino Substituted-2-Substituted-1,2,3,4-tetrahydroquinoline Compounds App 20060247272 - Ruggeri; Roger B. ; et al.	2006-11-02
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors Grant 7,115,279 - Curatolo , et al. October 3, 2	2006-10-03
Pharmaceutical Compositions of Dispersions of Drugs and Neutral Polymers App 20060216351 - Friesen; Dwayne T. ; et al.	2006-09-28
Pharmaceutical Compositions of Cholesteryl Ester Transfer Protein Inhibitor App 20060211654 - Curatolo; William J. ; et al.	2006-09-21
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds App 20060063803 - Ruggeri; Roger B. ; et al.	2006-03-23
Process for forming amorphous atorvastatin App 20050032880 - Lorenz, Douglas A. ; et al.	2005-02-10
Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor App 20040197398 - Friesen, Dwayne T. ; et al.	2004-10-07
Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor App 20040185102 - Friesen, Dwayne T. ; et al.	2004-09-23
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors App 20030186952 - Crew, Marshall D. ; et al.	2003-10-02
Pharmaceutical compositions of dispersions of drugs and neutral polymers App 20030091643 - Friesen, Dwayne T. ; et al.	2003-05-15
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors App 20020103225 - Curatolo, William J. ; et al.	2002-08-01
Pharmaceutical compositions providing enhanced drug concentrations App 20020006443 - Curatolo, William J. ; et al.	2002-01-17
Glycogen phosphorylase inhibitor App 20010053791 - Babcock, Walter C. ; et al.	2001-12-20
Pharmaceutical compositions of glycogen phosphorylase inhibitors App 20010053778 - Hoover, Dennis J. ; et al.	2001-12-20
Enantiomeric resolution of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone Grant 5,288,916 - Lorenz , et al. February 22, 1	1994-02-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.